Glenmark Pharmaceuticals’ Swiss subsidiary -- Glenmark Specialty S.A., has entered into an exclusive licensing agreement with Lotus International Pte a wholly owned subsidiary of Lotus Pharmaceutical (Lotus), for commercializing its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.
Under the terms of the agreement, the company will be responsible for the manufacture and supply of Ryaltris, whereas Lotus will be responsible for commercialization of Ryaltris (subject to receipt of regulatory approvals), in these markets. Glenmark will receive an upfront payment as well as regulatory and sales based milestone payments from Lotus.
Glenmark Pharmaceuticals is a global research-led pharmaceutical company with presence across Generics, Specialty and OTC business with operations in over 50 countries.
